Park Avenue Securities LLC Takes Position in Jazz Pharmaceuticals PLC $JAZZ

Park Avenue Securities LLC acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,165 shares of the specialty pharmaceutical company’s stock, valued at approximately $336,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals in the first quarter valued at about $25,000. Parallel Advisors LLC raised its holdings in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 119 shares in the last quarter. Picton Mahoney Asset Management raised its stake in Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 269 shares during the period. Spire Wealth Management raised its stake in Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 161 shares during the period. Finally, SVB Wealth LLC acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $36,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $131.80 on Wednesday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock’s 50 day moving average price is $122.55 and its 200-day moving average price is $115.72. The company has a market capitalization of $7.99 billion, a PE ratio of -19.58, a PEG ratio of 8.00 and a beta of 0.24. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the previous year, the firm earned $5.30 EPS. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on JAZZ shares. The Goldman Sachs Group increased their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target for the company. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Truist Financial raised their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Finally, Royal Bank Of Canada increased their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.93.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the sale, the director owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.